Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

Citi lowered the firm’s price target on AbbVie (ABBV) to $205 from $215 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the ...

Citi raised the firm’s price target on Bristol Myers (BMY) to $65 from $60 and keeps a Neutral rating on the shares. Ahead of the Q4 earnings, ...

(Reuters) - Alexandria Real Estate Equities (NYSE: ARE) posted a rise in its fourth-quarter funds from operations on Monday, as the real estate investment trust benefited from steady leasing demand ...

Failed to fetch dynamically imported module: https://uk.finance.yahoo.com/assets/_app/immutable/nodes/100.CtMQo59V.js ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Wall Street analysts weigh in on Amazon, Nvidia, Carnival, Seagate Technology Holdings, Netflix, and Affirm Holdings.

Rising homeowner’s insurance costs could disrupt some financial plans in the coming years. Last year was the second ...